Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Charles O'Brien

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Endo
Address834 Cancer Institute
4104 Outpatient Circle
Mail Slot # 587
Little Rock AR 72205
Phone501-214-2180
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentOrthopaedics, College of Medicine


    Collapse Research Funds 
    Collapse research activities
    R21AR076575     (ONAL, MELDA)Jan 1, 2020 - Dec 31, 2020
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    CRISPR inhibition as an alternate for Cre-loxP
    Role: Co-Investigator

    S10 OD026736     (MACKINTOSH, SAMUEL)Aug 1, 2019 - Jul 31, 2020
    NIH/Office of the Director
    Q Exactive HF-X Hybrid Quadrupole Orbitrap Mass Spectrometer
    Role: Co-Investigator

    P20GM125503     (O'BRIEN, CHARLES A)Feb 16, 2018 - Jan 31, 2023
    NIH/NIGMS
    Center for Musculoskeletal Disease Research (CMDR)
    Role: Principal Investigator

    P20GM109005     (BOERMA, MARJAN)Jun 24, 2015 - Mar 31, 2020
    NIH/NIGMS
    Center for Studies of Host Response to Cancer Therapy
    Role: Co-Investigator

         (O'BRIEN, CHARLES A)Oct 1, 2013 - Sep 30, 2017
    Veterans Administration
    RANKL and Lymphocyte Mediated Bone Loss
    Role: Principal Investigator

    I01BX000294     (O'BRIEN, CHARLES A)Apr 1, 2009 - Sep 30, 2017
    VA
    Molecular mechanisms of glucocorticoid-induced bone loss
    Role: Principal Investigator

    R01AR056679     (SCHULLER DE ALMEIDA, MARIA)Dec 1, 2008 - Jan 31, 2021
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    Role of FoxOs in Skeletal Homeostasis- Resubmission
    Role: Co-Investigator

    R01AR049794     (O'BRIEN, CHARLES A)Apr 1, 2003 - Mar 31, 2020
    NIH/NIAMS
    Osteocyte Control of Bone Remodeling
    Role: Principal Investigator

    R01AR045241     (O'BRIEN, CHARLES A)Sep 1, 1998 - Aug 31, 2004
    NIH/NIAMS
    IN VIVO REGULATION OF IL6 AND IL6R GENE EXPRESSION
    Role: Principal Investigator

    R29AR045241     (O'BRIEN, CHARLES A)Sep 1, 1998 - Aug 31, 2003
    NIH/NIAMS
    IN VIVO REGULATION OF IL6 AND IL6R GENE EXPRESSION
    Role: Principal Investigator

    P01AG013918     (MANOLAGAS, STAVROS C.)Aug 27, 1996 - May 31, 2011
    NIH/NIA
    Molecular and Cellular Mechanisms of Osteoporosis
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. MacLeod RS, Cawley KM, Gubrij I, Nookaew I, Onal M, O'Brien CA. Effective CRISPR interference of an endogenous gene via a single transgene in mice. Sci Rep. 2019 11 21; 9(1):17312. PMID: 31754144.
      View in: PubMed
    2. O'Brien CA, Morello R. Modeling Rare Bone Diseases in Animals. Curr Osteoporos Rep. 2018 08; 16(4):458-465. PMID: 29802575.
      View in: PubMed
    3. Xiong J, Cawley K, Piemontese M, Fujiwara Y, Zhao H, Goellner JJ, O'Brien CA. Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat Commun. 2018 07 25; 9(1):2909. PMID: 30046091.
      View in: PubMed
    4. Zimmerman SM, Heard-Lipsmeyer ME, Dimori M, Thostenson JD, Mannen EM, O'Brien CA, Morello R. Loss of RANKL in osteocytes dramatically increases cancellous bone mass in the osteogenesis imperfecta mouse (oim). Bone Rep. 2018 Dec; 9:61-73. PMID: 30105276.
      View in: PubMed
    5. Xiong J, Almeida M, O'Brien CA. The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation. Bone. 2018 07; 112:1-9. PMID: 29626544.
      View in: PubMed
    6. Weinstein RS, Hogan EA, Borrelli MJ, Liachenko S, O'Brien CA, Manolagas SC. The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice. Endocrinology. 2017 11 01; 158(11):3817-3831. PMID: 28938402.
      View in: PubMed
    7. Piemontese M, Almeida M, Robling AG, Kim HN, Xiong J, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA, Jilka RL. Old age causes de novo intracortical bone remodeling and porosity in mice. JCI Insight. 2017 09 07; 2(17). PMID: 28878136.
      View in: PubMed
    8. Lee SM, Meyer MB, Benkusky NA, O'Brien CA, Pike JW. The impact of VDR expression and regulation in vivo. J Steroid Biochem Mol Biol. 2018 03; 177:36-45. PMID: 28602960.
      View in: PubMed
    9. Kim HN, Chang J, Shao L, Han L, Iyer S, Manolagas SC, O'Brien CA, Jilka RL, Zhou D, Almeida M. DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age. Aging Cell. 2017 08; 16(4):693-703. PMID: 28401730.
      View in: PubMed
    10. Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A, Compadre CM, Goellner JJ, O'Brien CA, Fahmi T, Basnakian AG, Calingasan NY, Klessner JL, Beal FM, Peters OM, Metterville J, Brown RH, Ling KKY, Rigo F, Ozdinler PH, Kiaei M. Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet. 2017 02 15; 26(4):686-701. PMID: 28040732.
      View in: PubMed
    11. Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R, Vanderschueren D, Manolagas SC. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev. 2017 01; 97(1):135-187. PMID: 27807202.
      View in: PubMed
    12. Ucer S, Iyer S, Kim HN, Han L, Rutlen C, Allison K, Thostenson JD, de Cabo R, Jilka RL, O'Brien C, Almeida M, Manolagas SC. The Effects of Aging and Sex Steroid Deficiency on the Murine Skeleton Are Independent and Mechanistically Distinct. J Bone Miner Res. 2017 Mar; 32(3):560-574. PMID: 27714847.
      View in: PubMed
    13. Fujiwara Y, Piemontese M, Liu Y, Thostenson JD, Xiong J, O'Brien CA. RANKL (Receptor Activator of NF?B Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice. J Biol Chem. 2016 Nov 25; 291(48):24838-24850. PMID: 27733688.
      View in: PubMed
    14. Piemontese M, Xiong J, Fujiwara Y, Thostenson JD, O'Brien CA. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab. 2016 09 01; 311(3):E587-93. PMID: 27460899.
      View in: PubMed
    15. Piemontese M, Onal M, Xiong J, Han L, Thostenson JD, Almeida M, O'Brien CA. Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage. Sci Rep. 2016 Apr 11; 6:24262. PMID: 27064143.
      View in: PubMed
    16. Liu Y, Almeida M, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Skeletal inflammation and attenuation of Wnt signaling, Wnt ligand expression, and bone formation in atherosclerotic ApoE-null mice. Am J Physiol Endocrinol Metab. 2016 May 01; 310(9):E762-73. PMID: 26956187.
      View in: PubMed
    17. Jilka RL, O'Brien CA. The Role of Osteocytes in Age-Related Bone Loss. Curr Osteoporos Rep. 2016 Feb; 14(1):16-25. PMID: 26909563.
      View in: PubMed
    18. Lee SM, Meyer MB, Benkusky NA, O'Brien CA, Pike JW. Mechanisms of Enhancer-mediated Hormonal Control of Vitamin D Receptor Gene Expression in Target Cells. J Biol Chem. 2015 Dec 18; 290(51):30573-86. PMID: 26504088.
      View in: PubMed
    19. Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, Bonewald L, Manolagas SC, O'Brien CA. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One. 2015; 10(9):e0138189. PMID: 26393791.
      View in: PubMed
    20. Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, Manolagas SC, Almeida M. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol. 2015 Oct; 29(10):1498-509. PMID: 26287518.
      View in: PubMed
    21. Ucer S, Iyer S, Bartell SM, Martin-Millan M, Han L, Kim HN, Weinstein RS, Jilka RL, O'Brien CA, Almeida M, Manolagas SC. The Effects of Androgens on Murine Cortical Bone Do Not Require AR or ERa Signaling in Osteoblasts and Osteoclasts. J Bone Miner Res. 2015 Jul; 30(7):1138-49. PMID: 25704845.
      View in: PubMed
    22. Onal M, Bishop KA, St John HC, Danielson AL, Riley EM, Piemontese M, Xiong J, Goellner JJ, O'Brien CA, Pike JW. A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse. J Bone Miner Res. 2015 May; 30(5):855-68. PMID: 25431114.
      View in: PubMed
    23. Piemontese M, Onal M, Xiong J, Wang Y, Almeida M, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA. Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone. Bone. 2015 Jun; 75:18-26. PMID: 25700544.
      View in: PubMed
    24. Lee SM, Goellner JJ, O'Brien CA, Pike JW. A humanized mouse model of hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Endocrinology. 2014 Nov; 155(11):4137-48. PMID: 25147982.
      View in: PubMed
    25. Iyer S, Han L, Bartell SM, Kim HN, Gubrij I, de Cabo R, O'Brien CA, Manolagas SC, Almeida M. Sirtuin1 (Sirt1) promotes cortical bone formation by preventing ß-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem. 2014 Aug 29; 289(35):24069-78. PMID: 25002589.
      View in: PubMed
    26. Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA. Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone. 2014 Sep; 66:146-54. PMID: 24933342.
      View in: PubMed
    27. Bartell SM, Kim HN, Ambrogini E, Han L, Iyer S, Serra Ucer S, Rabinovitch P, Jilka RL, Weinstein RS, Zhao H, O'Brien CA, Manolagas SC, Almeida M. FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014 Apr 30; 5:3773. PMID: 24781012.
      View in: PubMed
    28. Lee SM, Bishop KA, Goellner JJ, O'Brien CA, Pike JW. Mouse and human BAC transgenes recapitulate tissue-specific expression of the vitamin D receptor in mice and rescue the VDR-null phenotype. Endocrinology. 2014 Jun; 155(6):2064-76. PMID: 24693968.
      View in: PubMed
    29. Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res. 2014 Jan; 29(1):103-17. PMID: 23761243.
      View in: PubMed
    30. Manolagas SC, O'Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013 Dec; 9(12):699-712. PMID: 24042328.
      View in: PubMed
    31. Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, de Cabo R, Jilka RL, Weinstein RS, O'Brien CA, Manolagas SC, Almeida M. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest. 2013 Aug; 123(8):3409-19. PMID: 23867625.
      View in: PubMed
    32. Almeida M, O'Brien CA. Basic biology of skeletal aging: role of stress response pathways. J Gerontol A Biol Sci Med Sci. 2013 Oct; 68(10):1197-208. PMID: 23825036.
      View in: PubMed
    33. O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 2013; 54(2):258-63.
    34. Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates bone porosity with age. J Bone Mineral Res. 2013.
    35. Onal M, Piemontese M, Xiong J, Wang Y, Han L, Ye S, Komatsu M, Selig M, Weinstein RS, Zhao H, Jilka RL, Almeida M, Manolagas SC, O'Brien CA. Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem. 2013 Jun 14; 288(24):17432-40. PMID: 23645674.
      View in: PubMed
    36. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, Ambrogini E, Onal M, Xiong J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013; 123(1):394 - 404.
    37. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, Ambrogini E, Onal M, Xiong J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. Estrogen receptor-a signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013 Jan; 123(1):394-404. PMID: 23221342.
      View in: PubMed
    38. O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 2013 Jun; 54(2):258-63. PMID: 22939943.
      View in: PubMed
    39. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, O'Brien CA. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012; 287(35):29851 - 29860.
    40. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, O'Brien CA. Receptor activator of nuclear factor ?B ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012 Aug 24; 287(35):29851-60. PMID: 22782898.
      View in: PubMed
    41. Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012; 27(3):499 - 505.
    42. Onal M, Galli C, Fu Q, Xiong J, Weinstein RS, Manolagas SC, O'Brien CA. The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocrinol. 2012 Feb; 26(2):341-8. PMID: 22207718.
      View in: PubMed
    43. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011 Sep 11; 17(10):1235-41. PMID: 21909103.
      View in: PubMed
    44. Weinstein RS, O'Brien CA, Almeida M, Zhao H, Roberson PK, Jilka RL, Manolagas SC. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology. 2011 Sep; 152(9):3323-31. PMID: 21771887.
      View in: PubMed
    45. Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, Olivos N, Passeri G, O'Brien CA, Bivi N, Plotkin LI, Bellido T. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2011 May; 26(5):1035-46. PMID: 21140374.
      View in: PubMed
    46. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010 Nov; 25(11):2427-37. PMID: 20533302.
      View in: PubMed
    47. Almeida M, Martin-Millan M, Ambrogini E, Bradsher R, Han L, Chen XD, Roberson PK, Weinstein RS, O'Brien CA, Jilka RL, Manolagas SC. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res. 2010 Apr; 25(4):769-81. PMID: 19821774.
      View in: PubMed
    48. O'Brien CA. Control of RANKL gene expression. Bone. 2010; 46(4):911 - 919.
    49. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010 Feb 03; 11(2):136-46. PMID: 20142101.
      View in: PubMed
    50. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010 Feb; 24(2):323-34. PMID: 20053716.
      View in: PubMed
    51. O'Brien,CA. Control of RANKL gene expression. Bone. 2010; 46:911-919.
    52. Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O'Brien CA, Thostenson J, Roberson PK, Boskey AL, Clemens TL, Manolagas SC. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010 Apr; 9(2):147-61. PMID: 20047574.
      View in: PubMed
    53. O'Brien CA. Control of RANKL gene expression. Bone. 2010 Apr; 46(4):911-9. PMID: 19716455.
      View in: PubMed
    54. Galli C, Fu Q, Wang W, Olsen BR, Manolagas SC, Jilka RL, O'Brien CA. Commitment to the osteoblast lineage is not required for RANKL gene expression. J Biol Chem. 2009 May 08; 284(19):12654-62. PMID: 19279010.
      View in: PubMed
    55. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009 Feb; 44(2):275-86. PMID: 19010455.
      View in: PubMed
    56. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008 Aug 13; 3(8):e2942. PMID: 18698360.
      View in: PubMed
    57. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology. 2008 Jan; 149(1):146-53. PMID: 17932217.
      View in: PubMed
    58. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007 Sep 14; 282(37):27298-305. PMID: 17623658.
      View in: PubMed
    59. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007 Sep 14; 282(37):27285-97. PMID: 17623659.
      View in: PubMed
    60. Aguirre JI, Plotkin LI, Gortazar AR, Millan MM, O'Brien CA, Manolagas SC, Bellido T. A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem. 2007 Aug 31; 282(35):25501-8. PMID: 17609204.
      View in: PubMed
    61. Manolagas SC, Jilka RL, Kousteni S, Bellido T, Weinstein RS, O'Brien CA, Plotkin L, Han L. Response to Windahl et al. J Clin Invest. 2006 Nov; 116(11):2834. PMID: 17080186.
      View in: PubMed
    62. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol. 2006 Sep; 26(17):6453-68. PMID: 16914731.
      View in: PubMed
    63. O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab. 2005 Nov; 289(5):E784-93. PMID: 15956054.
      View in: PubMed
    64. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004 Apr; 145(4):1835-41. PMID: 14691012.
      View in: PubMed
    65. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003 Dec 12; 278(50):50259-72. PMID: 14523023.
      View in: PubMed
    66. Fu Q, Jilka RL, Manolagas SC, O'Brien CA. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem. 2002 Dec 13; 277(50):48868-75. PMID: 12364326.
      View in: PubMed
    67. O'Brien CA, Kern B, Gubrij I, Karsenty G, Manolagas SC. Cbfa1 does not regulate RANKL gene activity in stromal/osteoblastic cells. Bone. 2002 Mar; 30(3):453-62. PMID: 11882458.
      View in: PubMed
    68. Shi H, O'Brien CA, Van Horn DJ, Wolin SL. A misfolded form of 5S rRNA is complexed with the Ro and La autoantigens. RNA. 1996; 2(8):769 - 784.
    69. Manolagas SC, Jilka RL, Bellido T, O'Brien CA, Parfitt, AM. Principles of bone biology. Interleukin-6-type cytokines and their receptors. 1996.
    70. Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff IN. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest. 1995; 96(4):1730 - 1737.
    71. Van Horn DJ, Eisenberg D, O'Brien CA, Wolin SL. Caenorhabditis elegans embryos contain only one major species of Ro RNP. RNA. 1995; 1(3):293 - 303.
    72. Farris AD, O'Brien CA, Harley JB. Y3 is the most conserved small RNA component of Ro ribonucleoprotein complexes in vertebrate species. Gene. 1995; 154(2):193 - 198.
    73. O'Brien CA, Wolin SL. A possible role for the 60-kD Ro autoantigen in a discard pathway for defective 5S rRNA precursors. Genes Dev. 1994; 8(23):2891 - 2903.
    74. O'Brien CA, Margelot K, Wolin SL. Xenopus Ro ribonucleoproteins: members of an evolutionarily conserved class of cytoplasmic ribonucleoproteins. Proc Natl Acad Sci U S A. 1993; 90(15):7250 - 7254.
    75. Ge Q, Frank MB, O'Brien C, Targoff IN. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest. 1992; 90(2):559 - 570.
    76. O'Brien CA, Harley JB. Association of hY4 pseudogenes with Alu repeats and abundance of hY RNA-like sequences in the human genome. Gene. 1992; 116(2):285 - 289.
    77. O'Brien CA, Harley JB. A subset of hY RNAs is associated with erythrocyte Ro ribonucleoproteins. EMBO J. 1990; 9(11):3683 - 3689.
    78. James JA, Dickey WD, Fujisaku A, O'Brien CA, Deutscher SL, Keene JD, Harley JB. Antigenicity of a recombinant Ro (SS-A) fusion protein. Arthritis Rheum. 1990; 33(1):102 - 106.
    79. Mamula MJ, O'Brien CA, Harley JB, Hardin JA. The Ro ribonucleoprotein particle: induction of autoantibodies and the detection of Ro RNAs among species. Clin Immunol Immunopathol. 1989; 52(3):435 - 446.
    80. Targoff IN, Arnett FC, Berman L, O'Brien C, Reichlin M. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest. 1989; 84(1):162 - 172.
    81. Rader MD, O'Brien C, Liu YS, Harley JB, Reichlin M. Heterogeneity of the Ro/SSA antigen. Different molecular forms in lymphocytes and red blood cells. J Clin Invest. 1989; 83(4):1293 - 1298.
    82. Jilka RL, Bellido T, Almeida M, Plotkin LI, O'Brien CA, Weinstein RS, Manolagas SC. Principles of bone biology. Apoptosis of Bone Cells.
    O'Brien's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _